PF-Atlas › Clinical Trials › NCT05878717
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Belimumab · Phase 2
Registry ID
NCT05878717
Phase
Phase 2
Status
Recruiting
Drug / intervention
Belimumab
Sponsor
GlaxoSmithKline
Start
2023-09-13
Enrollment
300
Locations
131
About this trial
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05878717 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.